Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice

<table class="table-group" width="800px"><tr class="fig-image" id="a"><td><img alt="806391.fig.001a" src="https://static.hindawi.com/articles/bmri/volume-2014/806391/figures/806391.fig.001a.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(a) </b>30 months (0–88+)</td></tr></table></td></tr><tr class="fig-image" id="b"><td><img alt="806391.fig.001b" src="https://static.hindawi.com/articles/bmri/volume-2014/806391/figures/806391.fig.001b.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(b) </b>10 months (0–46)</td></tr></table></td></tr><tr class="fig-image" id="c"><td><img alt="806391.fig.001c" src="https://static.hindawi.com/articles/bmri/volume-2014/806391/figures/806391.fig.001c.jpg"/></td></tr><tr class="fig-caption"><td align="center"><table><tr><td><b>(c) </b></td></tr></table></td></tr></table>

<table>Kaplan-Meier survival estimate. (a) Overall hepatocellular carcinoma patients, overall survival. (b) Unresectable hepatocellular carcinoma patients,  overall survival. (c) Unresectable hepatocellular carcinoma patients, BCLC stages B, C,  and D,  fit versus unfit for sorafenib.</table>

BioMed Research International

fig1

Figure 1

Figure 1: Multidisciplinary Management of Hepatocellular Carcinoma in Clinical Practice 